Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
about
Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.Data Sharing Requirements and Evolution of the Publication Process.The ICMJE Recommendations and pharmaceutical marketing--strengths, weaknesses and the unsolved problem of attribution in publication ethics.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisEffects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based PharmacokinetImpact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Promoting Education Regarding Conflict of Interest Management.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.High nonpublication rate from publication professionals hinders evidence-based publication practices.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.Factors impacting time to acceptance and publication for peer-reviewed publications.Two years into the Sunshine Act: synopsis of opportunities, challenges, learnings, and potential implications.Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals.Mythbusting Medical Writing: Goodbye, Ghosts! Hello, Help!Improving the Trustworthiness of Published Information.EAP viewpoint on unpublished data from paediatric clinical trials.Insula and amygdala resting-state functional connectivity differentiate bipolar from unipolar depression.Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers.Impact of data transparency: Scientific publications.Publication ethics from the ground up.Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.Authorship: Musings about guests and ghosts.A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care.Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.What is good publication practice, what is ISMPP, and why you should careKnowledge and attitudes of Indian surgeons regarding professional medical writing supportImproved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USAUpdated Editorial Guidance for Quality and Reliability of Research OutputEvolving role of pharmaceutical physicians in medical evidence and education
P2860
Q30488988-70E72F60-A3E9-4633-B143-C0FDCD79AB49Q33441702-14EFC456-A107-4B1E-8C00-E0143A678CAAQ36107268-46875728-7A53-4AF3-81C9-147BE7D06C89Q36356295-6287E957-DD99-45A4-A9AB-DC7B5491885CQ36359482-9D1BD8BD-D8F0-4AED-BFEC-2B0598638A5AQ36765612-06B372E5-2BD9-47F3-9119-AF5637FE4520Q37375516-9E7901A0-0C14-481A-BC61-D11B9CC89847Q38372360-F1218984-8C99-4AD3-9F6D-FD3073AA6347Q38738098-EFD0735F-D577-47BA-8DFB-3F8D1A87C8E1Q38801887-3763F184-4313-4786-A0B0-835F60B7B0A2Q38807562-DC6C3AB3-9DA7-4932-9FA6-2816B281BDBDQ38832181-4822C9BD-19A8-445B-98F5-D6C411575953Q38837144-515DCBFF-9F46-436D-A873-B6D0D7870229Q38912382-D5E72EEE-D27E-4E7A-AF98-9790412B08FDQ39098841-EB48AA45-8D8E-4928-A94C-5195F5F6CAB2Q39527166-5BF35A4B-DF28-4324-A7F3-3C9305931502Q42364786-7E1E0830-6873-4619-869C-88C5781DA78CQ45018512-971B7C94-7563-4199-B1BC-C6652331B833Q45029933-5720AB2E-A086-4BC5-BCF5-FED0B944017AQ45934154-63F7A160-5E62-418F-A362-ED58D98414EDQ47927195-CBEED697-88E6-49E1-B18B-707D17A01DB6Q48331868-B3C8B626-29F8-4D89-835A-9CAF12791286Q50072908-B08D0A2A-4B4D-4F94-9117-EB5C76212565Q50123353-4DED0FAD-CDD0-4128-945F-25A0A64642F1Q52562726-8C52F11B-29AE-44B2-972F-17F818308CD3Q52614710-77229AFC-D0FB-4C7A-839D-086C5520C67CQ53144089-E5EA75D3-D582-4D6B-BDC2-0018F9BC87A9Q53839703-8773F337-623B-4C3E-A2E0-E0C6B50F5463Q54958121-EAA83455-C4C6-4F32-A4C4-C9C14E027006Q55021618-FB112692-C942-492F-BA8F-AF86EE09A491Q55364939-6CA0FE39-EFA9-468A-A3A0-8E24FD583E1CQ56790630-C0AF9620-D3F6-40B5-9253-F2EAA35FADBAQ57178837-C58339AD-A9C8-4C31-9C36-C089CB0C16F9Q57491724-2C6EB124-F4A6-4880-9858-F57208F2D73DQ58338497-C4CCD5C7-3AC1-4283-86CA-64CBBC8338E8Q59125752-4454F061-F69E-4038-B589-CA301BA20ADC
P2860
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
@en
type
label
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
@en
prefLabel
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
@en
P2093
P50
P356
P1476
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
@en
P2093
Angela Cairns
B Jane Moore
Carol H Sanes-Miller
Christopher I Carswell
International Society for Medical Publication Professionals
James A Gurr
Karen L Woolley
Keith Veitch
Lise Baltzer
Teresa Peña
P304
P356
10.7326/M15-0288
P407
P577
2015-08-11T00:00:00Z